When the World Health Organization declared the H1N1 pandemic in June 2009, Novartis was already busy preparing seasonal influenza vaccines for the 2009–2010 season. “We typically prepare 70–80 million doses for a typical season,” explains Matt Stober of Novartis Technical Operations. “We had to ramp up quickly to be able to provide an additional 150 million doses of H1N1.” In total, Novartis produced over 200 million influenza vaccines.
West Pharmaceutical Services Inc. and Grifols USA L.L.C. announce the availability of West’s Mix2Vial filtered transfer system for the reconstitution of Grifols’ coagulation therapies. The Mix2Vial system, developed and manufactured by West’s subsidiary Medimop Medical Projects Ltd., is a patented device designed for easy reconstitution of lyophilized drugs.
Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Oramed's Oral Insulin Capsules
JERUSALEM, Israel, July 7, 2010/PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, today announced that Oramed entered into a Manufacturing Supply Agreement (MSA) with sanofi-aventis. According to the MSA, sanofi-aventis will supply Oramed with specified quantities of recombinant human insulin to be used by Oramed for its clinical trials in the USA.
Combination products offer therapeutic benefits to patients and help caregivers deliver treatments more efficiently. These advantages are driving growth in areas such as respiratory drug delivery systems and prefilled syringes, while spurring innovation in formats such as transdermal patches.
Harland Medical Systems and Tapemark (West St. Paul, MN) have joined forces to commercialize new innovations in medical coatings. The collaboration partnership will focus on applying medical coatings to high-volume medical devices such as glucose test strips, microfluidic diagnostic strips, introducer patches, wound management dressings, and other coated medical devices or components.
Just as pharmaceutical companies are providing comprehensive programs to help patients and professionals tackle health goals of the diabetes patient and improve their overall lifestyle, pharmaceutical packaging manufacturers are also playing a crucial role in diabetes in the area of devices. The therapeutic category of diabetes is unique to packaging because the delivery system is such an integral part of the overall brand experience.
3M Drug Delivery Systems (St. Paul, MN) introduces the 3M Nasal Metered Dose Inhaler, a no-drip method of nasal drug delivery designed to drive patient preference. This new nasal inhaler has been shown through research to be patient preferred, with no post-nasal runoff, aftertaste or drip, giving pharmaceutical partners a novel and effective way to deliver inhaled corticosteroids for allergic rhinitis and other nasal treatments.
SHL is continuing to expand operations in the United States with the establishment of SHL Pharma Systems, a state-of-the-art final assembly and packaging operation. Located in South Florida, this new facility will offer final assembly, labeling, and packaging services to SHL's pharmaceutical and biotechnology customers.
FDA has announced that seven metered-dose inhalers (MDI) used to treat asthma and chronic obstructive pulmonary disease (COPD) are being gradually removed from the U.S. marketplace. According to the agency's Web site, these inhalers contain ozone-depleting chlorofluorocarbons (CFCs), which are propellants that move medication out of the inhaler and into the lungs of patients. The removal is in accordance with agreements under the Montreal Protocol on Substances that Deplete the Ozone Layer.